Giner-Calabuig, Mar
De Leon, Seila
Wang, Julian
Fehlmann, Tara D.
Ukaegbu, Chinedu
Gibson, Joanna
Alustiza-Fernandez, Miren
Pico, Maria-Dolores
Alenda, Cristina
Herraiz, Maite
Carrillo-Palau, Marta
Salces, Inmaculada
Reyes, Josep
Ortega, Silvia P.
Obrador-Hevia, Antònia
Cecchini, Michael
Syngal, Sapna
Stoffel, Elena
Ellis, Nathan A.
Sweasy, Joann
Jover, Rodrigo
Llor, Xavier
Xicola, Rosa M. http://orcid.org/0000-0001-6466-1885
Funding for this research was provided by:
Regional Government of Valencia | Conselleria d'Educació, Investigació, Cultura i Esport (ACIF/2010/018, ACIF/2016/002)
Donaldson Foundation
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI17/01756)
Asociación Española de Gastroenterología, Beca Tamarite 2017
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1K01CA204431-01A1)
Prevent Cancer Foundation
Colorectal Cancer Alliance (Chris4Life Research Program)
Article History
Received: 6 April 2021
Revised: 24 January 2022
Accepted: 10 February 2022
First Online: 23 February 2022
Competing interests
: SS is a consultant for Myriad Genetics and DC Health Technologies and has rights to an inventor portion of the licensing revenue from PREMM5. The remaining authors declare no competing interests.
: Patients were recruited and consented in their original institutions under projects approved by institutional human research review committees. At Yale University the project was approved by the Biomedical Institutional Review Board. All data were shared in a de-identified manner to unlink any patient’s personal identifiers from their samples. The study was performed in accordance with the Declaration of Helsinki.